PT - JOURNAL ARTICLE AU - C. Field, Nicholas AU - Rogers, Aubrey AU - Custozzo, Amanda J. AU - Boulos, Alan S. AU - Dalfino, John AU - Paul, Alexandra R. TI - Using an Artificial Intelligence Application Expedited ENRICH Trial Patient Screening: A Single Center Experience AID - 10.1101/2023.02.24.23286438 DP - 2024 Jan 01 TA - medRxiv PG - 2023.02.24.23286438 4099 - http://medrxiv.org/content/early/2024/06/13/2023.02.24.23286438.short 4100 - http://medrxiv.org/content/early/2024/06/13/2023.02.24.23286438.full AB - Objective The ENRICH Trial was the first to demonstrate superiority of surgical intervention over medical management when performed within 24 hours of symptom onset for supratentorial lobar hemorrhages. We aimed to determine whether the implementation of an intracranial hemorrhage detection algorithm that provides immediate active notification to provider cell phones would expediate the screening of hemorrhagic stroke patients for the trial at our institution.Methods A retrospective review of our prospectively collected ENRICH Trial patient screening log was performed at our Comprehensive Stroke Center. The log encompassed patients screened for the ENRICH Trial who presented between January 2018 and March 2022. Trial screening data was compared pre- and post-implementation of the VizAI (Viz.ai, San Francisco, California, USA) smartphone application.Results 188 adult patients were identified during the study period. Time between CT Head and notification of the neurosurgical team for trial screening was reduced by 50 minutes after the implementation of VizAI (p<0.002). The number increases to 57 minutes when hemorrhages not identified by the ICH algorithm were excluded.Conclusions Active notification of the neurosurgical team by an artificial intelligence application significantly reduces the time from hemorrhage identification to trial screening. Further studies are needed to evaluate whether this results in a clinical benefit.Competing Interest StatementJD is a consultant for MicroVention. AP is a consultant for MicroVention, Medtronic, Penumbra, IRRAS and NICO.Funding StatementAll funding for this study was provided by the Department of Neurosurgery at Albany Medical Center.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study obtained Institutional Review Board approval from Albany Medical College.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.